To assess in more detail the oncogenic role of m6A modification in CML, we performed METTL3 and METTL14 silencing in the BCR-ABL1+ CML cell line K562 (Fig. 2). This evidence concerns the gene METTL3 and chronic myelogenous leukemia, BCR-ABL1 positive.